Astonea Labs Ltd (544409)

Astonea Labs has updated its Corporate Identification Number (CIN) to L21001CH2017PLC041482 from L24304CH2017PLC041482. This follows shareholder approval on 21st August, 2026, to alter the Object Clause of its Memorandum of Association. The Ministry of Corporate Affairs registered the alteration on 09th October, 2026, leading to a reclassification under the National Industrial Classification code. This administrative change does not alter the company's financial base (TTM revenue of Rs 292 Cr).

• CIN updated from L24304CH2017PLC041482 to revised CIN L21001CH2017PLC041482
• Shareholder approval for Object Clause alteration was granted at AGM on 21st August, 2026
• MCA registered the alteration of Object Clause under Section 13(1) on 09th October, 2026
• Reclassification driven by updated National Industrial Classification (NIC) Code

Astonea Labs has incorporated a new subsidiary, Longevity Science Private Limited, on October 8, 2026. The company will acquire a 51% stake by subscribing to 51,000 equity shares at ₹10 each, totaling a cash consideration of ₹5,10,000. The subsidiary will focus on pharmaceuticals, healthcare, nutraceuticals, and allied products. Given the initial investment size of just ₹5.10 lakh relative to Astonea's ₹292 Cr TTM revenue, the financial commitment is currently negligible.

• Incorporated new subsidiary Longevity Science Private Limited on October 8, 2026
• Astonea Labs to hold 51% stake via 51,000 equity shares
• Cash investment stands at ₹10 per share, totaling ₹5,10,000
• Target operational area spans pharmaceuticals, healthcare, and nutraceuticals

Astonea Labs has resubmitted its Standalone Financial Results for the half year ended March 31, 2025, in response to a communication from BSE Limited dated September 18, 2026. The company stated that while the results were originally filed in XBRL mode, the separate PDF version was inadvertently omitted under Regulation 33 of SEBI LODR. This filing is purely a procedural rectification to upload the missing PDF copy and does not alter previously reported financials (H2 FY25 revenue of ₹97.52 Cr and PAT of ₹5.35 Cr).

• Resubmission pertains to the financial results for the half year ended 31st March 2025
• Filing follows a compliance discrepancy notice from BSE Limited dated 18th September 2026
• Company confirmed original submission was done in XBRL mode, but the PDF version was omitted

Astonea Labs Limited has secured shareholder approval via a Special Resolution at its 9th Annual General Meeting held on 21 August 2026 to alter Clause III(A) of its Memorandum of Association (MOA). The amendment expands the company's main object clause to cover the manufacturing, processing, and distribution of pharmaceuticals, nutraceuticals, ayurvedic products, dietary supplements, and veterinary medicines. It also explicitly permits multi-channel distribution, including e-commerce platforms and digital marketplaces, to support future business diversification.

• Shareholders approved the alteration of Clause III(A) (Main Objects) of the MOA via Special Resolution on 21 August 2026.
• Approval was granted during the company's 9th Annual General Meeting.
• Expanded object scope covers pharmaceuticals, nutraceuticals, ayurvedic items, dietary supplements, cosmetics, and veterinary goods.
• Authorizes distribution across diverse channels including retail, institutional sales, franchise models, and e-commerce platforms.

Shareholders of Astonea Labs Limited approved the re-appointment of Ms. Pooja Singh as Director at the company's 9th Annual General Meeting held on 21st August, 2026. Ms. Singh, who was liable to retire by rotation, has over eight years of pharmaceutical industry experience in Quality Assurance and Drug Regulatory Affairs. She joined the company in 2021 and currently heads its Drug Regulatory Affairs department. Ms. Singh holds nil equity shares and is not related to any Director or Key Managerial Personnel.

• Re-appointment of Ms. Pooja Singh (DIN: 10547745) approved at the 9th AGM on 21st August, 2026
• Director has over 8 years of pharmaceutical industry experience and joined the firm in 2021
• Holds NIL equity shares in Astonea Labs Limited and has no inter-se relation with other directors

Astonea Labs Limited has submitted its Annual Report for the financial year ended March 31, 2026, as per SEBI regulations. The report includes the notice for the 9th Annual General Meeting (AGM), the Board's Report, and audited financial statements. Based on previous data, the company reported a revenue of ₹97.0 cr and a net profit of ₹5.0 cr for FY25. The company currently carries a debt of ₹43 cr against a net worth of ₹58 cr, resulting in a debt-to-equity ratio of 0.74.

• Submission of the Annual Report for the financial year ended March 31, 2026
• Includes the Notice convening the 9th Annual General Meeting of the Company
• Board of Directors approved the report at its meeting held on July 24, 2026
• FY25 revenue was ₹97.0 cr with an operating profit margin of 16.0%
• Promoter holding remained stable at 72.3% as of March 2026

Astonea Labs has scheduled its 9th Annual General Meeting (AGM) for August 21, 2026, to approve FY26 financial results and key corporate changes. The company is seeking shareholder approval via special resolutions to alter its Memorandum of Association (MOA) and authorize investments in new Indian subsidiaries. This comes after a strong performance where Mar 2026 quarterly revenue reached ₹81 Cr, representing approximately 83% of the entire FY25 revenue of ₹97 Cr. Other routine items include the re-appointment of Director Pooja Singh and ratification of a ₹75,000 cost auditor fee.

• 9th Annual General Meeting scheduled for August 21, 2026, in Chandigarh.
• Special resolution proposed for the incorporation and investment in new subsidiary companies in India.
• Special resolution proposed for the alteration of the Object Clause in the Memorandum of Association (MOA).
• Remote e-voting period set from August 18, 2026, to August 20, 2026.
• Proposed ratification of ₹75,000 remuneration for Cost Auditor M/s. Balwinder & Associates for FY27.

Astonea Labs has amended its board resolution dated May 30, 2026, to update statutory references for the re-appointment of its Tax Auditor, M/s. Avnish Sharma & Associates. The update replaces references to the Income-tax Act, 1961 with the Income-tax Act, 2025 (specifically Section 63) for the Tax Year 2026-27. This is a procedural change with no impact on the auditor's remuneration or terms. The company recently reported a revenue of ‡81.0 cr for the quarter ended March 2026.

• Re-appointment of M/s. Avnish Sharma & Associates as Tax Auditor for Tax Year 2026-27
• Amendment to Item No. 15 of the Board Resolution dated 30th May, 2026
• Statutory reference updated to Section 63 of the Income-tax Act, 2025
• No change in remuneration or other terms and conditions of the appointment
• Company reported FY25 revenue of ‡97.0 cr and PAT of ‡5.0 cr

Astonea Labs has approved its audited consolidated financial results for the year ended March 31, 2026, which were previously delayed from May 2026 due to pending audits of its associate, Damaira Pharmaceuticals. The board also approved the incorporation of new subsidiaries in India to expand business segments and proposed altering the Memorandum of Association (MOA) to include e-commerce and digital marketplace distribution. The 9th Annual General Meeting (AGM) is scheduled for August 21, 2026, to seek shareholder approval for these changes.

• Consolidated FY26 results approved after a delay from the original May 30, 2026 board meeting
• 9th Annual General Meeting scheduled for August 21, 2026, at 11:30 A.M. in Chandigarh
• Proposed alteration of MOA Object Clause to include manufacturing and retail via e-commerce and digital platforms
• Board approval for incorporation and investment in one or more wholly-owned subsidiaries in India
• Re-appointment of Ms. Pooja Singh as Director recommended for shareholder approval

Astonea Labs has completed the sale of two commercial units in the JMD Megapolis IT Park, Gurugram, for a total consideration of approximately ₹2.99 crore. Each unit (FF-508 and FF-509) measures 1,361 sq. ft. and was sold for approximately ₹1.49 crore to non-related individual buyers. The company has received the full consideration and registered the sale deeds as of July 17, 2026. This move is part of the company's strategy to monetize non-core assets and optimize its financial position.

• Sale of two commercial units totaling 2,722 sq. ft. in Sector 48, Gurugram
• Total sale consideration of approximately ₹2,99,42,000 (₹1.49 cr per unit)
• Transaction completed and registered on July 17, 2026
• Buyers identified as non-related parties, ensuring an arms-length transaction
• Full consideration received as per the terms of the Sale Deed